Davar D, Cavalcante L, Lakhani N, et al. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). J ImmunoTherapy Cancer 2024;12:e009474. doi: 10.1136/jitc-2024–0 09 474
In the original article, panel B of Figure 1 was a duplicate of panel A:
The correct panel has now been added to the figure: